Jiangsu Bioperfectus Technologies Co Ltd
SSE:688399
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
45.89
78.75
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Jiangsu Bioperfectus Technologies Co Ltd
Operating Income
Jiangsu Bioperfectus Technologies Co Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Jiangsu Bioperfectus Technologies Co Ltd
SSE:688399
|
Operating Income
-ÂĄ76.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
|
Operating Income
ÂĄ2.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
S
|
Shanghai Conant Optical Co Ltd
HKEX:2276
|
Operating Income
ÂĄ525.5m
|
CAGR 3-Years
28%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Winner Medical Co Ltd
SZSE:300888
|
Operating Income
ÂĄ827.4m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Operating Income
ÂĄ2B
|
CAGR 3-Years
21%
|
CAGR 5-Years
18%
|
CAGR 10-Years
22%
|
|
|
Intco Medical Technology Co Ltd
SZSE:300677
|
Operating Income
ÂĄ991.9m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
Jiangsu Bioperfectus Technologies Co Ltd
Glance View
Jiangsu Bioperfectus Technologies Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents and supporting testing instruments. The company is headquartered in Taizhou, Jiangsu and currently employs 765 full-time employees. The company went IPO on 2019-12-05. The firm's products mainly include in vitro diagnostic reagents, supporting testing instruments and in vitro testing services. Its products are mainly used in the fields of infectious disease prevention and control, clinical testing, large-scale population screening, as well as prenatal and postnatal care management. The firm mainly conducts its businesses in domestic and overseas markets.
See Also
What is Jiangsu Bioperfectus Technologies Co Ltd's Operating Income?
Operating Income
-76.7m
CNY
Based on the financial report for Sep 30, 2025, Jiangsu Bioperfectus Technologies Co Ltd's Operating Income amounts to -76.7m CNY.
What is Jiangsu Bioperfectus Technologies Co Ltd's Operating Income growth rate?
Operating Income CAGR 1Y
65%
Over the last year, the Operating Income growth was 65%.